Advertisement
Cardiovascular
Subscribe to Cardiovascular
View Sample

FREE Email Newsletter

Amarin Reports First Quarter 2011 Results

May 10, 2011 12:32 am | by Bio-Medicine.Org | News | Comments

DUBLIN and MYSTIC, Conn., May 10, 2011 /- Amarin Corporation plc (NASDAQ: AMRN ), a clinical-stage biopharmaceutical company focused on cardiovascular disease, today reported financial results for the quarter ended March 31, 2011 (Q1 2011). The Company also provided an update on its...

The Human Body, Searchable in 3-D

May 9, 2011 8:34 pm | by Massachusetts Institute of Technology | News | Comments

A new tool lets people see the inside of the body up close and in great detail.

Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICIDâ„¢ Phase 3 Data

May 9, 2011 9:33 am | by Bio-Medicine.Org | News | Comments

CHICAGO, May 9, 2011 /- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) today announced the presentation of two abstracts at the 2011 Digestive Disease Week (DDW) conference highlighting additional analyses of data from Phase 3 trials of DIFICID™ (fidaxomicin), an investigational...

Advertisement

Simcere Announces Recent Progress of Qiangke's Registration

May 9, 2011 3:35 am | by Bio-Medicine.Org | News | Comments

NANJING, China, May 9, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR ), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced that...

Orexigen® Therapeutics Reports First Quarter Ended March 31, 2011 Financial Results

May 9, 2011 3:35 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, May 9, 2011 /- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2011.  For the three months ended March 31, 2011, Orexigen reported a net loss of...

Reportlinker Adds Brazil Biomaterial Market (2010 - 2015)

May 9, 2011 3:35 am | by Bio-Medicine.Org | News | Comments

NEW YORK, May 9, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Brazil Biomaterial Market (2010 – 2015) http://www.reportlinker.com/p0490400/Brazil-Biomaterial-Market-2010-–-2015.html Report Description : The Brazil market...

New Device to Support Blood Circulation for Heart Patients Shows Improved Outcomes Compared to Current Treatment

May 6, 2011 9:45 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 6, 2011 /- A new device designed to assist blood circulation and support blood pressure in high-risk patients undergoing percutaneous coronary intervention (PCI) has shown improved outcomes compared to the standard treatment with an intraaortic balloon pump. Results of the...

FDA Expands Approved Use For Carotid Stent

May 6, 2011 9:45 am | by Bio-Medicine.Org | News | Comments

SILVER SPRING, Md., May 6, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved an expanded indication that will allow a new group of patients at risk of stroke due to clogged neck arteries to be treated with the RX Acculink carotid stent. (Logo:...

Advertisement

InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference

May 6, 2011 6:41 am | by Bio-Medicine.Org | News | Comments

TEL AVIV, Israel, May 6, 2011 /- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard™ mesh protective stent system, today announced that Mr. Ofir Paz, InspireMD's co-founder and chief executive officer, and Mr. Craig Shore, chief financial...

Alexza to Present at the MDB Bright Lights Conference 2011

May 6, 2011 6:40 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., May 6, 2011 /- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) today announced that company Senior Vice President and Chief Financial Officer, August J. Moretti will present during the MDB Bright Lights Conference 2011.  The Alexza presentation will be on Tuesday,...

CryoLife Announces Final Results of Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation

May 6, 2011 6:40 am | by Bio-Medicine.Org | News | Comments

ATLANTA and IRVINE, Calif., May 6, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the final results of its tender offer, including proration results, through its wholly owned subsidiary CL Falcon,...

HeartWare to Present at the 2011 Bank of America Merrill Lynch Health Care Conference

May 6, 2011 3:46 am | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass., and SYDNEY, May 6, 2011 /- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug...

Boston Scientific Begins International Launch and First Implants of Next-Generation Devices to Treat Heart Failure and Sudden Cardiac Death

May 6, 2011 1:33 am | by Boston Scientific | News | Comments

World's smallest and thinnest high-energy CRT-Ds and ICDs offer new features to optimize patient management

Advertisement

SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs

May 5, 2011 11:34 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- A new position statement released today by the Society for Cardiovascular Angiography and Interventions (SCAI) calls for changes in the way quality of percutaneous coronary intervention (PCI, also known as angioplasty) care is measured and publically reported....

SCAI Announces National Quality Program to Improve Cardiovascular Patient Care

May 5, 2011 11:33 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- Today at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions, SCAI announced its national quality improvement program to measure and improve quality in the cath lab for better patient care. Building on its legacy of using...

New Data Provide First Look at Ability to Detect Life-Threatening Heart Problems in Some High-Risk Patients

May 5, 2011 8:32 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- New data presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions are the first to look at the use of highly specialized signals within implantable cardioverter defibrillators (ICDs) to detect restricted blood...

HERCULES Trial Demonstrates Significant Reduction in Systolic Blood Pressure While Revealing Marker in Hypertensive Patients Does Not Predict Outcomes of Renal Artery Stenting

May 5, 2011 8:32 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- A substance secreted by the heart that is associated with congestive heart failure and renal failure is not predictive of reduction in systolic blood pressure in patients treated with renal artery stenting, according to results from the HERCULES trial presented...

SCAI Releases First Report on Transradial Access for Angioplasty and Stenting

May 5, 2011 8:32 am | by Bio-Medicine.Org | News | Comments

BALTIMORE, May 5, 2011 /- As interventional cardiologists increasingly perform angiography or angioplasty and stent procedures via radial (wrist) access versus femoral (groin or upper leg) access, it will be imperative to develop training and competency guidelines, according to the first...

Echo Therapeutics Expands Into New Headquarters in Philadelphia

May 5, 2011 6:38 am | by Bio-Medicine.Org | News | Comments

PHILADELPHIA, May 5, 2011 /- Echo Therapeutics, Inc. (OTCBB: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude™ SkinPrep System for transdermal drug delivery, today...

Resource Now Available to Help Clinicians Reduce Risk of Blood Exposure from Short Peripheral IV Catheter Insertion

May 3, 2011 6:33 am | by Bio-Medicine.Org | News | Comments

SANDY, Utah, May 3, 2011 /- Healthcare workers now have the ability to better identify risks for exposure to bloodborne pathogens, take precautions to better protect themselves, and share information and experiences as a result of a new program developed by BD Medical, a segment of BD...

Abaxis, Inc. to Present at the Bank of America Merrill Lynch 2011 Health Care Conference

May 3, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

UNION CITY, Calif., May 3, 2011 /- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, announced today that Clint Severson, chairman and chief executive officer,  will present at the Bank of America Merrill Lynch 2011 Health...

CryoLife Completes Tender Offer for 49.9 Percent of the Outstanding Shares of Cardiogenesis Corporation

May 3, 2011 5:34 am | by Bio-Medicine.Org | News | Comments

ATLANTA and IRVINE, Calif., May 3, 2011 /- CryoLife, Inc. (NYSE: CRY ), an implantable biological medical device and cardiovascular tissue processing company, today announced the completion of its tender offer, through its wholly owned subsidiary CL Falcon, Inc., for 49.9 percent of the...

NMT Medical, Inc. Assigned All Its Assets to Joseph F. Finn, Jr., C.P.A. of the Firm Finn, Warnke & Gayton, LLP on April 20, 2011

May 2, 2011 9:33 am | by Bio-Medicine.Org | News | Comments

WELLESLEY HILLS, Mass., May 2, 2011 /- On April 20, 2011, NMT Medical, Inc. ("NMT Medical") assigned all its assets to Joseph F. Finn, Jr., C.P.A. ("Finn") of the firm Finn, Warnke & Gayton, LLP to be liquidated for the benefit of NMT Medical creditors. NMT Medical's intellectual...

Boston Scientific Announces Its Schedule for Heart Rhythm Society Scientific Sessions

May 2, 2011 4:34 am | by Boston Scientific | News | Comments

NATICK, Mass., May 2, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced its schedule of major events and sponsored research at the 32nd Annual Scientific Sessions of the Heart Rhythm Society (HRS)

Abaxis Appoints Vernon Altman to Board of Directors

May 2, 2011 3:36 am | by Bio-Medicine.Org | News | Comments

UNION CITY, Calif., May 2, 2011 /- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today announced Vernon Altman has been appointed to the Company's Board of Directors, effective immediately. The addition of Mr. Altman brings...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading